New strategy to treat glomerular inflammation by inhibition of mesangial cell matrix metalloproteinases

Schweizerische Medizinische Wochenschrift

Volumn 130, Issue 21, 2000, Pages 784-788

  Marti, H P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Apoptosis; Glomerulonephritis; Matrix metalloproteinase(s); Mesangial cell

Indexed keywords

BB 1101; COLLAGENASE; GELATINASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; RO 111 3456; STROMELYSIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG EFFICACY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GLOMERULONEPHRITIS; HUMAN;

ANIMALS; APOPTOSIS; CELL DIVISION; CULTURE TECHNIQUES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; PENTOXIFYLLINE; PROTEASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034720540     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lee G, Glassock RJ. Immunoglobulin A nephropathy. In: Ponticelli C, Glassock RJ, eds. Treatment of Primary Glomerulonephritis. Oxford Clinical Nephrology Series. Oxford, New York, Tokyo: Oxford University Press; 1997. p. 186-217.
2. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.
3. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloproteinase domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 1995;131:275-8.
4. Kazes I, Delarue F, Hagège J, Bouzhir-Sima L, Rondeau E, Sraer J-D, et al. Soluble latent membrane-type 1 matrix metalloproteinase secreted by human mesangial cells is activated by urokinase. Kidney Int 1998;54:1976-84.
5. Skotnicki JS, Zask A, Nelson FC, Albright JD, Levin JI. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann N Y Acad Sci 1999;878:61-72.
6. McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994;370:558-61.
7. Lelongt B, Trugnan G, Murphy G, Ronco P. Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro. J Cell Biol 1997;136: 1363-73.
8. Marti HP, McNeil L, Thomas G, Davies M, Lovett DH. Molecular characterization of a low molecular weight matrix metalloproteinase secreted by glomerular mesangial cells as Pump-1. Biochem J 1992;285:899-905.
9. Koide H, Nakamura T, Ebihara I, Tomino Y. Increased mRNA expression of metalloproteinase-9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy. Am J Kidney Dis 1996;28:32-9.
10. Ebihara I, Nakamura T, Noriaki S, Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin dependent diabetes mellitus. Am J Kidney Dis 1998;32:544-50.
11. Marti HP, McNeil L, Davies M, Martin J, Lovett DH. Homology cloning of rat 72 kDa type IV collagenase: cytokine and second-messenger inducibility in glomerular mesangial cells. Biochem J 1993;291:441-6.
12. Marti HP, Lee L, Kashgarian M, Lovett DH. Transforming growth factor-β stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol 1994; 144:82-94.
13. Turck J, Pollock AS, Lee LK, Marti HP, Lovett DH. Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 1996;271:15074-83.
14. Turck J, Pollock AS, Lovett DH. Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney Int 1997;.51:1397-400.
15. Steinmann-Niggli K, Lukes M, Marti HP. Rat mesangial cells and matrix metalloproteinase inhibitor: inhibition of 72-kDa type IV collagenase (MMP-2) and of cell proliferation. J Am Soc Nephrol 1997;8:395-405.
16. Erba E, Ronzoni S, Bassano L, Giavazzi R, D'lncalci M. The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells. Ann Oncol 1999;10:589-91.
17. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 1999;59:1252-8.
18. Daniel C, Duffield J, Thomas G, Ziswiler RA, Steinmann-Niggli K, Marti HP. Matrix metalloproteinase inhibitor induces apoptosis in mesangial cells in vitro and in vivo. J Am Soc Nephrol 1999;10:569A.
19. Lovett DH, Johnson RJ, Marti HP, Martin J, Davies M, Couser WG. Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol 1992;141:85-98.
20. Steinmann-Niggli K, Küng M, Ziswiler R, Marti HP. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol 1998;9:397-407.
21. Ziswiler R, Daniel C, Kappeler A, Steinmann-Niggli K, Marti HP. Mycophenolic acid: a new approach to the therapy of mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998;9:2055-66.
22. Gijbels K, Galdary RE, Steinmann L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994; 94:2177-82.
23. Conway JG, Wakefield JA, Brown RH, Marron BE, Sekut L, Stimpson SA, et al. Inhibition of cartilage and hone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 1995;182:449-57.
24. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-89.